Skip to content

Author

Sneha Kumari

We have 6 of 61 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Stem cells and derived growth factors in Alzheimer's disease: mechanistic insights and translational perspectives.

Alzheimer's disease (AD) is a significant healthcare concern due to the complex interactions between amyloid-β accumulation, tau pathology, neuroinflammation, synaptic dysfunction, and progressive neuronal death. Stem-cell-based therapies have demonstrated potential to treat this complex condition through immunomodulat...

Rishika Dhapola, Sneha Kumari, Prajjwal Sharma et al. · 0 citations
Open access Aug 2026

Neuroprotective effect of normal and modified mesenchymal stem cell‐derived exosomes by mitigating Alzheimer's‐related oxidative and inflammatory damage via Nrf2/HO‐1 in SH‐SY5Y cells

Abstract Exosome therapy is emerging as a promising neuroprotective strategy for Alzheimer's disease (AD). We evaluated and compared whether normal exosomes (NE) and modified exosomes (ME) derived from AD rat brain extract‐treated rat bone marrow mesenchymal stem cells possess the potential to protect SH‐SY5Y cells aga...

Rishika Dhapola, Prajjwal Sharma, Sneha Kumari et al. · 0 citations
Open access Sep 2026

Influence of Biochar and Inorganic Fertilizer on Soil Properties, Growth, Yield and Quality Parameters of French Bean (Phaseolus vulgaris L.)

French bean (Phaseolus vulgaris L.) is an important legume vegetable crop; the integrated use of biochar with inorganic fertilisers may improve soil properties, nutrient availability and nutrient-use efficiency. Therefore, evaluating this approach is important for achieving sustainable and productive French bean cultiv...

A. Maurya, Anil Kumar Singh, Om Kumar et al. · 0 citations
Review Aug 2026

HMGB1 signalling in Alzheimer's disease: pathogenic roles and therapeutic prospects.

High mobility group box 1 (HMGB1) is a crucial modulator of neuroinflammation in AD, according to new research, and a viable treatment approach for reducing neuroinflammation and associated pathologies with AD is to target HMGB1-mediated signalling networks.

Prashant Tyagi, Sneha Kumari, Prajjwal Sharma et al. · 1 citation
Review 2026

Recent strategies and approaches for the development of molecularly targeted nanomedicine.

This chapter highlights the role of targeting ligands, stimuli-responsive systems, and tumor microenvironment-specific strategies in enhancing therapeutic efficacy while minimizing adverse effects, emphasizing the potential of molecularly targeted nanomedicine to advance precision therapy and improve clinical outcomes.

Aman Kumar, Md Hidul Islam, Pranav Dhingra et al. · 0 citations
Review Aug 2026

Neuroinflammatory and molecular pathways in Alzheimer’s disease: mechanistic crosstalk and emerging therapeutic opportunities

Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.

Abhay Thakur, Rohit Sharma, Sneha Kumari et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.